Sartorius Stedim Biotech in analyst focus, shares under Goldman Sachs scrutiny
23.06.2026 - 20:26:24 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 18:24.
Sartorius Stedim Biotech (FR0013154002) sits in the analyst spotlight after a fresh note from Goldman Sachs on parent company Sartorius and its preferred shares traded in Germany. Goldman keeps a Neutral stance and trims the target price, with a cautious view on the upcoming second-quarter report and a stated preference for Sartorius Stedim Biotech as a subsidiary, according to dpa-AFX coverage of the Goldman study published on June 23, 2026. dpa-AFX summary of the Goldman Sachs update
Goldman Sachs’ cautious stance
Goldman Sachs analyst James Quigley has lowered the price target for the Sartorius shares listed in Germany from 230 euros to 229 euros and reiterated a Neutral rating in his latest report. dpa-AFX summary of the Goldman Sachs update The house expects an unspectacular second-quarter report from the laboratory supplier, describing management as likely to remain conservative and not inclined to raise full-year guidance at this stage. Quigley describes the shares as historically expensive and explicitly prefers the equity of subsidiary Sartorius Stedim Biotech over the parent, highlighting the French-based bioprocess specialist as his favored exposure to the group. dpa-AFX summary of the Goldman Sachs update
What other analysts say
The Goldman Sachs note lands in an environment where other houses also show a cautious tone on Sartorius, while investors differentiate between the parent and Sartorius Stedim Biotech. DZ Bank recently reaffirmed its Neutral rating on Sartorius preferred shares, underscoring muted near-term upside as the stock trades at a premium to peers in the medical instruments and supplies segment. DZ Bank rating as summarized by MarketScreener MarketScreener data for Sartorius preferred shares show an average target price around 266 euros based on recent coverage, implying upside from the last close yet paired with a significant spread of opinions on valuation and earnings momentum in the wider bioprocessing sector. MarketScreener consensus snapshot on Sartorius
More news and data on Sartorius Stedim Biotech
All recent articles, background pieces and price information on the Sartorius Stedim Biotech shares are collected on the dedicated topic page and the company’s investor relations site.
How Sartorius Stedim Biotech earns its money
Sartorius Stedim Biotech’s core business is supplying integrated equipment and consumables for biopharmaceutical production, a segment that has grown structurally with the expansion of biologic drugs and advanced therapies. The company focuses on single-use bioprocess solutions such as disposable bioreactors, filtration systems and sterile bags that enable flexible manufacturing in upstream and downstream processing steps. In addition, Sartorius Stedim Biotech offers process analytics, control software and validation services that support drug developers and contract manufacturers in scaling cell culture-based production from clinical batches to commercial volumes.
Where the Sartorius Stedim Biotech stock trades today
The Sartorius Stedim Biotech shares (FR0013154002) trade on Euronext Paris under ticker DIM, with the latest verifiable price data and timestamp provided by the Paris listing feeds in euros.
Key data on the Sartorius Stedim Biotech shares
- Company: Sartorius Stedim Biotech S.A.
- ISIN: FR0013154002
- WKN: A2AAQ0
- Ticker: DIM
- Trading venue: Euronext Paris
- Price (as of 2026-06-23, 18:24): not live-verifiable EUR
- Market cap: not live-verifiable EUR (as of 2026-06-23)
- Sector / industry: Medical Instruments & Supplies, bioprocess equipment
- Index membership: not live-verifiable
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. All data have been compiled with care but without any guarantee; investors should consult official filings, pricing services and professional advisors before making investment decisions.
